Jason Kolbert
Stock Analyst at Dawson James
(0.53)
# 3,015
Out of 4,412 analysts
28
Total ratings
45.83%
Success rate
-17.52%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Initiates: Buy | $3 | $0.17 | +1,680.42% | 1 | Feb 28, 2024 | |
| BJDX Bluejay Diagnostics | Downgrades: Neutral | n/a | $0.75 | - | 2 | Aug 3, 2023 | |
| GOVX GeoVax Labs | Initiates: Buy | $60 | $1.42 | +4,125.35% | 1 | Mar 3, 2023 | |
| CETX Cemtrex | Maintains: Buy | $7.62 → $22 | $1.71 | +1,180.70% | 1 | Feb 6, 2023 | |
| GNPX Genprex | Initiates: Buy | $120 | $2.15 | +5,481.40% | 1 | Jan 30, 2023 | |
| ZOM Zomedica | Initiates: Buy | $6 | $0.13 | +4,411.28% | 1 | Jan 6, 2023 | |
| BCDA BioCardia | Downgrades: Neutral | n/a | $0.38 | - | 2 | Nov 11, 2022 | |
| ADTX Aditxt | Downgrades: Neutral | n/a | $2.39 | - | 1 | Sep 16, 2022 | |
| SMFL Smart for Life | Initiates: Buy | $25,200 | $4.05 | +622,122.22% | 1 | Aug 29, 2022 | |
| DYAI Dyadic International | Downgrades: Neutral | n/a | $1.49 | - | 1 | Jul 18, 2022 | |
| KTRA Kintara Therapeutics | Downgrades: Neutral | n/a | $0.15 | - | 1 | May 16, 2022 | |
| PRPH ProPhase Labs | Downgrades: Neutral | n/a | $4.71 | - | 1 | Oct 13, 2021 | |
| CHEK Check-Cap | Downgrades: Neutral | n/a | $2.29 | - | 1 | Mar 17, 2021 | |
| SNGX Soligenix | Downgrades: Neutral | n/a | $0.42 | - | 2 | Jul 28, 2020 | |
| CHRS Coherus BioSciences | Initiates: Buy | n/a | $2.04 | - | 3 | Aug 28, 2018 | |
| MNKD MannKind | Terminates: Sell | n/a | $4.23 | - | 3 | Jun 15, 2018 | |
| SNOA Sonoma Pharmaceuticals | Downgrades: Hold | n/a | $0.16 | - | 2 | Mar 6, 2018 | |
| BCLI Brainstorm Cell Therapeutics | Maintains: Buy | n/a | $0.53 | - | 1 | Aug 17, 2017 | |
| IDXG Interpace Biosciences | Initiates: Buy | n/a | $1.50 | - | 1 | Aug 15, 2017 | |
| BLRX BioLineRx | Upgrades: Buy | n/a | $0.61 | - | 1 | May 18, 2017 |
Tonix Pharmaceuticals Holding
Feb 28, 2024
Initiates: Buy
Price Target: $3
Current: $0.17
Upside: +1,680.42%
Bluejay Diagnostics
Aug 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
GeoVax Labs
Mar 3, 2023
Initiates: Buy
Price Target: $60
Current: $1.42
Upside: +4,125.35%
Cemtrex
Feb 6, 2023
Maintains: Buy
Price Target: $7.62 → $22
Current: $1.71
Upside: +1,180.70%
Genprex
Jan 30, 2023
Initiates: Buy
Price Target: $120
Current: $2.15
Upside: +5,481.40%
Zomedica
Jan 6, 2023
Initiates: Buy
Price Target: $6
Current: $0.13
Upside: +4,411.28%
BioCardia
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.38
Upside: -
Aditxt
Sep 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.39
Upside: -
Smart for Life
Aug 29, 2022
Initiates: Buy
Price Target: $25,200
Current: $4.05
Upside: +622,122.22%
Dyadic International
Jul 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Kintara Therapeutics
May 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.15
Upside: -
ProPhase Labs
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.71
Upside: -
Check-Cap
Mar 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.29
Upside: -
Soligenix
Jul 28, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Coherus BioSciences
Aug 28, 2018
Initiates: Buy
Price Target: n/a
Current: $2.04
Upside: -
MannKind
Jun 15, 2018
Terminates: Sell
Price Target: n/a
Current: $4.23
Upside: -
Sonoma Pharmaceuticals
Mar 6, 2018
Downgrades: Hold
Price Target: n/a
Current: $0.16
Upside: -
Brainstorm Cell Therapeutics
Aug 17, 2017
Maintains: Buy
Price Target: n/a
Current: $0.53
Upside: -
Interpace Biosciences
Aug 15, 2017
Initiates: Buy
Price Target: n/a
Current: $1.50
Upside: -
BioLineRx
May 18, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.61
Upside: -